copper(II) complex is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C for solid; 2-8 °C for short-term solution use | Avoid repeated freeze-thaw cycles |
| Preferred solvent | Water or aqueous buffer near neutral pH | Nonpolar solvents give poor dissolution |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Copper quantified separately by ICP-MS |
| Principal degradation routes | Backbone hydrolysis, histidine oxidation, photolysis | Alkaline pH accelerates hydrolysis |
| Counterion form | Acetate salt is common | Counterion contributes to measured mass |
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Similar patterns in other Xanthoria species suggest that, despite limited variation within local populations, long-distance dispersal and genetic drift contribute to regional differentiation and ecological adaptation. At broader spatial scales, X. parietina populations show a pattern of isolation by distance—genetic differences increase with geographic separation. A global genetic study using RAPD-PCR fingerprinting identified just two major genetic clusters worldwide: one in southwestern Europe (Iberian Peninsula, Balearic and Canary Islands) and another spanning Europe, North America, Australia, and New Zealand. The high similarity between Australian/New Zealand samples and those from Europe indicates the species was introduced by humans to the Southern Hemisphere, possibly via grapevine transport or ship ballast stones. A similar human introduction has been suggested for the lichen in the populated Willamette Valley of the western United States, and in Ontario, where it may have arrived on nursery trees. The high genetic diversity observed in X. parietina has several practical implications for its ecology and conservation. This diversity likely supports the species' adaptability to different environments—from coastal rocks to urban trees and polluted areas. High genetic variation within local populations provides material for natural selection, enabling adaptation to changing conditions including pollution levels and climate shifts. The different genetic structures between the fungal and algal partners suggest that X.
== Discovery == RGD was identified as the minimal recognition sequence within fibronectin required for cell attachment by Ruoslahti and Pierschbacher in the early 1980s. To do this, the authors synthesized various peptides based on the hypothesized cell attachment site of fibronectin. They then coupled those peptides to protein-coated plastic and tested each for cell attachment-promoting activity. Only those that contained the RGD sequence were found to enhance cell attachment. Further, they showed that peptides containing RGD were able to inhibit cell attachment to fibronectin-coated substrates, whereas peptides not containing RGD did not. These foundational studies also identified the cellular receptors that recognize the sequence. These studies utilized a synthetic RGD-containing peptide to isolate the putative receptors, and then demonstrated that liposomes containing the isolated proteins could bind to fibronectin, in much the same way as cells with surface receptors. The discovered receptors were later named integrins. The RGD motif is presented in slightly different ways in different proteins, making it possible for the many RGD-binding integrins to selectively distinguish individual adhesion proteins.
== Plot summary == Anathem is set on the fictional planet of Arbre. Thousands of years before the events in the novel, the planet's intellectuals entered concents (monastic communities) to protect their activities from the collapse of society. The avout (intellectuals separated from Sæcular society) are banned from possessing or operating most advanced technology and are supervised by the Inquisition, which answers to the outside world. The avout are normally allowed to communicate with people outside the walls of the concent only once every year, decade, century, or millennium, depending on the particular vows they have taken. The narrator and protagonist, Fraa Erasmas, is an avout at the Concent of Saunt Edhar. His teacher, Fraa Orolo, discovers that an alien spacecraft is orbiting Arbre – a fact that the world government (Sæcular Power) attempts to cover up. Erasmas becomes aware of Orolo's discovery after Orolo is banished (in a rite called Anathem) from the concent for using a video camera (a forbidden technology) to observe the ship. The presence of the alien ship soon becomes an open secret among many of the avout at Saunt Edhar. The alien ship eventually declares its presence by shining a laser upon several Millenarian Maths (the bastions of those avout who have taken a thousand-year vow of isolation). Shortly after that, the Sæcular Power summons many avout from Saunt Edhar, including Erasmas and a Millenarian named Fraa Jad. The avout are told to travel to the concent of Saunt Tredegarh to attend a Convox (a joint conference of the avout and the Sæcular Power).
== Sources == Alhakim, Youssef (1983). Syria and the French Mandate (in Arabic). Beirut: Dar Al-Nahar. Bishour, Wadi' (1994). Syria: The Making of a State and the Birth of a Nation (in Arabic) (1st ed.). Damascus, Syria: Dar Al-Yaziji. Haddad, Ghassan Mohammed Rashad (2007). Shami Papers: Contemporary Syrian History 1946-1966 (in Arabic). Madbouly Library. ISBN 9789772086276. Archived from the original on 10 August 2020. Retrieved 9 February 2025. Torrey, Gordon (1964). Syrian Politics and the Military, 1945-1958. Ohio State University Press. Archived from the original on 10 August 2020.
Sources: en.wikipedia.org
Peyote was first described by Bernardino de Sahagún in 1560. It was first scientifically named as Peyotl zacatensis by Francisco Hernández in 1638. Botanical studies of peyote began in the 1840s and the drug was listed in the Mexican pharmacopeia. The first use of mescal buttons was published by John Raleigh Briggs in 1887. However, he took a very low dose of the drug, and in the modern literature, the symptoms he experienced have been attributed to a severe panic attack in response to the drug. In 1887, the German pharmacologist Louis Lewin received his first sample of the peyote cactus, found numerous new alkaloids and later published the first methodical analysis of it. The effects of mescaline in humans were first properly described by D. W. Prentiss and Francis P. Morgan in 1895. Mescaline was first isolated and identified in 1897 by the German chemist Arthur Heffter. He showed that mescaline was exclusively responsible for the psychoactive or hallucinogenic effects of peyote. However, other components of peyote, such as hordenine, pellotine, and anhalinine, are also active. Mescaline was first synthesized in 1919 by Ernst Späth. Three major books on mescaline and/or peyote were published in the mid-to-late 1920s.
== Viral resistance to interferons == Many viruses have evolved mechanisms to resist interferon activity. They circumvent the IFN response by blocking downstream signaling events that occur after the cytokine binds to its receptor, by preventing further IFN production, and by inhibiting the functions of proteins that are induced by IFN. Viruses that inhibit IFN signaling include Japanese Encephalitis Virus (JEV), dengue type 2 virus (DEN-2), and viruses of the herpesvirus family, such as human cytomegalovirus (HCMV) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8). Viral proteins proven to affect IFN signaling include EBV nuclear antigen 1 (EBNA1) and EBV nuclear antigen 2 (EBNA-2) from Epstein-Barr virus, the large T antigen of Polyomavirus, the E7 protein of Human papillomavirus (HPV), and the B18R protein of vaccinia virus. Reducing IFN-α activity may prevent signaling via STAT1, STAT2, or IRF9 (as with JEV infection) or through the JAK-STAT pathway (as with DEN-2 infection). Several poxviruses encode soluble IFN receptor homologs—like the B18R protein of the vaccinia virus—that bind to and prevent IFN interacting with its cellular receptor, impeding communication between this cytokine and its target cells. Some viruses can encode proteins that bind to double-stranded RNA (dsRNA) to prevent the activity of RNA-dependent protein kinases; this is the mechanism reovirus adopts using its sigma 3 (σ3) protein, and vaccinia virus employs using the gene product of its E3L gene, p25.
Tapering off of methadone maintenance DE patent 711069, Dr Max Bockmuehl & Dr Gustav Ehrhart, "Verfahren zur Darstellung von basischen Estern", published 25 September 1941, issued 25 September 1941, assigned to IG Farbenindustrie AG Archived 13 February 2023 at the Wayback Machine
Severe side effects are rare and occur mostly in those with poor immune function. Its use in people with HIV/AIDS should be done with care. It is not recommended during pregnancy; however, the few times it has been given during pregnancy no problems resulted. The vaccine is available either by itself or along with the MMR vaccine, in a version known as the MMRV vaccine. It is made from weakened virus. A live attenuated varicella vaccine, the Oka strain, was developed by Michiaki Takahashi and his colleagues in Japan in the early 1970s. American vaccinologist Maurice Hilleman's team developed a chickenpox vaccine in the United States in 1981, based on the "Oka strain" of the varicella virus. The chickenpox vaccine first became commercially available in 1984. It was first licensed for use in the US by Merck, under the brand name Varivax, in 1995. It is on the World Health Organization's List of Essential Medicines.
"Chamber acid" and "tower acid" were the two concentrations of sulfuric acid produced by the lead chamber process, chamber acid being the acid produced in the lead chamber itself (<70% to avoid contamination with nitrosylsulfuric acid) and tower acid being the acid recovered from the bottom of the Glover tower. They are no longer used in commercial applications, although they may be prepared in the laboratory from concentrated sulfuric acid if needed. In particular, "10 M" sulfuric acid (the modern equivalent of chamber acid, used in many titrations) is prepared by slowly adding 98% sulfuric acid to an equal volume of water, with good stirring: the temperature of the mixture can rise to 80 °C (176 °F) or higher.
Sources: en.wikipedia.org
Encouraged by South Africa's apparent failure to detect the initial incursion, larger insurgent groups made their own infiltration attempts in February and March 1966. The second unit, "Group 2", was led by Leonard Philemon Shuuya, also known by the nom de guerre "Castro" or "Leonard Nangolo". Group 2 apparently become lost in Angola before it was able to cross the border, and the guerrillas dispersed after an incident in which they killed two shopkeepers and a vagrant. Three were arrested by the Portuguese colonial authorities in Angola, who were working off tips received from local civilians. Another eight, including Shuuya, had been captured between March and May by the South African police, apparently in Kavangoland. Shuuya later resurfaced at Kongwa, claiming to have escaped his captors after his arrest. He helped plan two further incursions: a third SWALA group entered Ovamboland that July, while a fourth was scheduled to follow in September.
mutation Any permanent change in the nucleotide sequence of a strand of DNA or RNA, or in the amino acid sequence of a peptide. Mutations play a role in both normal and abnormal biological processes; their natural occurrence is integral to the process of evolution. They can result from errors in replication, chemical damage, exposure to high-energy radiation, or manipulations by mobile genetic elements. Repair mechanisms have evolved in many organisms to correct them. By understanding the effect that a mutation has on phenotype, it is possible to establish the function of the gene or sequence in which it occurs.
=== Recreational use === Although some studies have reported flupirtine has no addictive properties, there was suggestion that it may possess some miuse potential and liability. There were at least two registered cases of flupirtine misuse. Drug tolerance does not develop in most cases, but has individually occurred. Flupirtine was reported as a novel designer drug in 2025. The effects of flupirtine have been said to be very difficult to describe. They have been reported to include "strong helicopter-like effects at high doses" causing users to have to "walk leaning against a wall", dissociative effects, feelings of euphoria throughout the body, and a very light buzzing sensation. Some have compared it to mephedrone, while others have described the physical bodily sensations as similar to those of MDMA and other entactogens. The drug is said to be able to produce psychosis and mania as adverse effects and to do so more readily than cathinone stimulants. The euphoria produced by flupirtine is said to last 40 to 60 minutes, whereas other effects last all day. The effects are said to convert after 2 hours from stimulant or euphoriant effects into a kind of nootropic effect that affects thinking. The drug is frequently used to enhance the effects of other recreational drugs.
The GTP-binding domain is conserved in both EF-1alpha/EF-Tu and also in EF-2/EF-G and thus seems typical for GTP-dependent proteins which bind non-initiator tRNAs to the ribosome. The GTP-binding translation factor family also includes the eukaryotic peptide chain release factor GTP-binding subunits and prokaryotic peptide chain release factor 3 (RF-3); the prokaryotic GTP-binding protein lepA and its homologue in yeast (GUF1) and Caenorhabditis elegans (ZK1236.1); yeast HBS1; rat Eef1a1 (formerly "statin S1"); and the prokaryotic selenocysteine-specific elongation factor selB.
Oxygen (1s2 2s2 2p4), fluorine (1s2 2s2 2p5), and neon (1s2 2s2 2p6) then complete the already singly filled 2p orbitals; the last of these fills the second shell completely. Starting from element 11, sodium, the second shell is full, making the second shell a core shell for this and all heavier elements. The eleventh electron begins the filling of the third shell by occupying a 3s orbital, giving a configuration of 1s2 2s2 2p6 3s1 for sodium. This configuration is abbreviated [Ne] 3s1, where [Ne] represents neon's configuration. Magnesium ([Ne] 3s2) finishes this 3s orbital, and the following six elements aluminium, silicon, phosphorus, sulfur, chlorine, and argon fill the three 3p orbitals ([Ne] 3s2 3p1 through [Ne] 3s2 3p6). This creates an analogous series in which the outer shell structures of sodium through argon are analogous to those of lithium through neon, and is the basis for the periodicity of chemical properties that the periodic table illustrates: at regular but changing intervals of atomic numbers, the properties of the chemical elements approximately repeat. The first 18 elements can thus be arranged as the start of a periodic table. Elements in the same column have the same number of valence electrons and have analogous valence electron configurations: these columns are called groups. The single exception is helium, which has two valence electrons like beryllium and magnesium, but is typically placed in the column of neon and argon to emphasise that its outer shell is full.
Sources: en.wikipedia.org
The solid is typically held cold and dry, and solutions are kept for shorter periods because hydrolysis proceeds in water. Repeated freeze-thaw cycles are usually avoided, since they can degrade both the peptide and the complex. Container material and headspace also affect how long a sample remains unchanged.
Copper is quantified by an elemental technique such as inductively coupled plasma mass spectrometry, not by peptide chromatography. The chromatographic result describes the peptide chain, while the elemental result describes the metal. Reporting both is what makes the stoichiometry checkable.
It normally lists the analytical methods used, the measured purity, the appearance, and any residuals or counterions detected. It is a statement about a specific batch rather than a general property of the material. Independent testing is still needed when results must be traceable to a reference standard.
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).